证券代码：600568 证券简称：ST 中珠 公告编号：2026-002 号 中珠医疗控股股份有限公司 关于补选第十届董事会各专门委员会委员的公告 特别提示 2026 年 1 月 5 日，公司召开第十届董事会第十六次会议，审议通过《关于 补选第十届董事会各专门委员会委员的议案》。 经公司董事长提名，董事会同意补选独立董事郑颖怡女士为战略委员会委 员、审计委员会委员、提名委员会委员、薪酬与考核委员会委员。郑颖怡女士 具有注册会计师从业资格，为会计专业人士，董事会同意选举郑颖怡女士担任 审计委员会召集人。 经公司董事长提名，董事会同意补选董事房巍屹女士为审计委员会委员、 薪酬与考核委员会委员；同意补选董事刘会平先生为提名委员会委员。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 中珠医疗控股股份有限公司（以下简称"中珠医疗"或"公司"）董事会于 2026 年 1 月 5 日召开第十届董事会第十六次会议，审议通过《关于补选第十届 董事会各专门委员会委员的议案》，现将具体情况公告如下： 一、董事离任及补选情况 2025 年 11 月 ...

证券代码：600568 证券简称：ST 中珠 公告编号：2026-001 号 中珠医疗控股股份有限公司 第十届董事会第十六次会议决议公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 二、董事会会议审议情况 经与会董事认真审议，通过以下议案： （一）审议通过《关于补选第十届董事会各专门委员会委员的议案》； 表决结果：同意 9 票，反对 0 票，弃权 0 票。 经公司董事长提名，董事会同意补选独立董事郑颖怡女士为战略委员会委 员、审计委员会委员、提名委员会委员、薪酬与考核委员会委员。郑颖怡女士 具有注册会计师从业资格，为会计专业人士，董事会同意选举郑颖怡女士担任 审计委员会召集人。 经公司董事长提名，董事会同意补选董事房巍屹女士为审计委员会委员、 薪酬与考核委员会委员；同意补选董事刘会平先生为提名委员会委员。 1、中珠医疗控股股份有限公司（以下简称"中珠医疗"或"公司"）第十 届董事会第十六次会议的召开符合有关法律、行政法规、部门规章、规范性文 件和《公司章程》的规定。 2、本次董事会会议于 ...

Group 1: Industry Recovery and Trends - In 2025, China's venture capital industry emerged from a two-year downturn, showing signs of recovery across the entire investment chain, driven by a combination of funding and project highlights, as well as supportive policies [1] - The year-end activities of venture capitalists indicate a strong return to the industry, fueled by a new wave of technological changes and ongoing policy benefits [1] Group 2: Government Investment Fund Policies - The State Council issued a significant document aimed at promoting the high-quality development of government investment funds, focusing on stricter controls on new fund establishments and optimizing investment policies [2] - Various local governments have responded by issuing supporting policy documents, further regulating the operation of government investment funds to promote high-quality industry development [2] Group 3: Banking Sector Involvement - Since the announcement of expanded pilot programs for bank-affiliated financial asset investment companies (AICs), banks have accelerated their entry into the primary market, with several major banks successfully establishing AICs [3] - As of now, AICs from six major state-owned banks and three national joint-stock banks have been established, with total investments reaching 45.272 billion yuan, a year-on-year increase of approximately 37.7% [3] Group 4: Special Bonds for Government Guidance Funds - Several local governments have issued special bonds to support government guidance funds, breaking the previous norm that prohibited such investments [4] - A total of 52 billion yuan in special bonds have been issued by nine provinces and cities, significantly enhancing the funding pool for the venture capital industry [4] Group 5: Long-Term Government Guidance Funds - New government guidance funds established this year have extended their duration beyond the typical 10 years, with some lasting up to 20 years, providing long-term support for projects [5] - This trend of extending fund durations is expected to create a more patient investment environment, allowing for better exit strategies [5] Group 6: Mergers and Acquisitions - The introduction of policies supporting private equity funds in acquiring listed companies has led to a surge in related acquisition cases, with several venture capital firms actively pursuing stakes in public companies [6][7] - The trend of startups acquiring listed companies is also on the rise, indicating a new strategy for both startups and venture capital firms to explore exit routes [7] Group 7: Domestic PE Firms Acquiring Foreign Brands - Domestic top-tier private equity firms have increasingly acquired the Chinese operations of overseas consumer brands, highlighting a trend of local capital participating in the localization of foreign brands [8] - This trend is driven by the combination of ample funding, local operational expertise, and the stable cash flow of established foreign brands [8] Group 8: Technology Innovation Bonds - The introduction of technology innovation bonds has opened new fundraising channels for venture capital institutions, with several private firms successfully issuing bonds at competitive interest rates [9] - The issuance of these bonds has significantly boosted market confidence and marked a transition towards a more normalized support phase for private venture capital institutions [9] Group 9: Mainland VC/PE Expansion into Hong Kong - Several mainland investment institutions have established offices in Hong Kong, attracted by the region's supportive environment for technological innovation [10] - The Hong Kong government's initiatives, including the establishment of a significant innovation and technology fund, have further encouraged mainland VC/PE firms to expand into the market [10] Group 10: Return of Dollar LPs to China - Multiple venture capital firms have successfully raised dollar-denominated funds, indicating a renewed interest from international investors in the Chinese market [11][12] - The return of dollar LPs coincides with the rapid growth of China's AI industry, highlighting the potential undervaluation of Chinese assets [11][12] Group 11: National Entrepreneurship Investment Fund - The establishment of a "carrier-level" national entrepreneurship investment fund aims to support startups across key economic regions in China, with a focus on early-stage investments [13] - This fund features a long duration of 20 years and aims to provide substantial financial backing to venture capital institutions and startups, enhancing the overall investment landscape [13]

重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一) 股东会召开的时间：2025 年 12 月 25 日 证券代码：600568 证券简称：ST 中珠 公告编号：2025-070 号 中珠医疗控股股份有限公司 2025年第四次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (五) 公司董事和董事会秘书的列席情况 1、公司在任董事7人，列席4人，董事戴绍宏先生、董事盛剑明先生、独立董事 栗胜男女士因公务未能出席本次会议； 2、董事长陈旭先生暂代董事会秘书职务并出席会议；总裁麻华先生、副总裁刘 会平先生、副总裁司培超先生、财务总监谭亮先生列席本次会议。 二、 议案审议情况 (一) 累积投票议案表决情况 1、 《关于补选公司第十届董事会非独立董事候选人的议案》 (二) 股东会召开的地点：珠海市情侣南路 1 号仁恒滨海中心 5 座 8 层 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 186 | | --- | --- | | ...

北京德恒（深圳）律师事务所 关于中珠医疗控股股份有限公司 2025年第四次临时股东会的 法律意见 北京德恒律师事务所 DeHeng Law Offices 深圳市福田区金田路 4018 号安联大厦 B 座 11 层 电话:0755-88286488 传真:0755-88286499 邮编:518026 北京德恒(深圳)律师事务所 关于中珠医疗控股股份有限公司 2025 年第四次临时股东会的法律意见 北京德恒(深圳)律师事务所 关于中珠医疗控股股份有限公司 2025年第四次临时股东会 的法律意见 德恒 06G20250412-01 号 致:中珠医疗控股股份有限公司 中珠医疗控股股份有限公司(以下简称"公司")2025 年第四次临时股东 会(以下简称"本次会议")于 2025年12月25日(星期四)召开。北京德恒 (深圳)律师事务所(以下简称"德恒"或"本所")受公司委托,指派邓宇戈 律师、李艾岭律师(以下简称"本所律师")出席了本次会议。根据《中华人民 共和国证券法》(以下简称"《证券法》")、《中华人民共和国公司法》(以 下简称"《公司法》")、中国证券监督管理委员会《上市公司股东会规则》(以 下简称"《股东 ...

Core Insights - The introduction of "Jinbiao Niu Qing Flavor" Baijiu represents a dual strategic significance: product value innovation and a youthful transformation in channels and communication methods [14] - The Chinese Baijiu market is entering a new competitive phase centered on "sensory optimization" and "scene penetration" [15] Product Innovation - "Jinbiao Niu Qing Flavor" Baijiu is a systematic reconstruction based on flavor science, sensory science, and brewing technology, aiming to provide a relaxed, low-burden, and high-comfort intoxication experience [3][5] - The choice of 36% alcohol by volume (vol) is based on the "flavor threshold theory," which indicates that key flavor compounds have the lowest sensory threshold in alcohol solutions of 30-40% vol, making 36% vol a "golden point" for flavor delivery [3][5] Production Techniques - Four major technological breakthroughs have been achieved: optimized microbial culture, low-temperature slow brewing, nano-purification, and golden ratio blending, ensuring that the product's "low burden" claim is a stable quality attribute rather than mere marketing [6][5] Market Positioning - The product is embedded in modern consumption scenarios such as "balcony barbecues" and "living room bars," capturing the changing landscape of Baijiu consumption driven by the rise of younger consumer groups [7][12] - The design and marketing strategies focus on appealing to younger consumers through trendy packaging, refreshing flavors, and interactive digital experiences [7][12] Consumer Engagement - The product's design combines classic and modern aesthetics, while its promotion of various drinking methods aims to create a "fun and relaxed social attribute" [9][12] - By integrating a QR code on the bottle that links to an official mini-program, the company has created an interactive experience that transforms drinking from a one-time event into an ongoing, shareable entertainment experience [12] Strategic Implications - Priced at 78 yuan per bottle, "Jinbiao Niu Qing Flavor" is a contemporary interpretation of the "people's liquor" concept, aiming to lower the drinking threshold and meet the health-conscious preferences of younger consumers [14] - This initiative reflects a strategic move by the company to solidify its market position while exploring new growth opportunities in a diversifying consumer landscape [14][15]

【深圳商报讯】(记者陈燕青)今年以来出现了多起私募股权创投基金入股上市公司的案例，涉及的A股 公司包括皮阿诺、鸿合科技、天迈科技、ST中珠等，大多为小市值公司。 对此，业内人士认为，未来私募股权创投基金收购上市公司股权的案例会越来越多，通过产业整合和资 产注入有助于改善相关公司的业绩。 12月15日晚，定制家居上市公司皮阿诺宣布，大股东马礼斌与二股东珠海鸿禄分别向初芯微转让9.78% 和7%股份，两项转让完成后，初芯微持股比例将达到16.78%。此外，大股东马礼斌同步承诺放弃其剩 余的3537.37万股表决权。此外，公司拟向青岛初芯定向发行3451.5万股，发行完成后青岛初芯持股比例 将达到15.87%。由于青岛初芯和初芯微为一致行动人，两者合计持股比例达29.99%。 根据记者梳理，私募股权创投基金入主上市公司主要有协议转让、参与上市公司定增、司法拍卖等方 式。从已披露的案例来看，私募股权创投基金大多通过"协议转让+原控股股东表决权委托(或放弃)"等 方式取得上市公司实控权。 私募股权创投基金下场收购上市公司控制权，既能缓解被投项目退出难的问题，又能以上市公司为平台 推进募资，可谓是一举两得。 深圳一家创投 ...

Group 1 - The core viewpoint of the article highlights that ST Zhongzhu (SH 600568) held its 14th meeting of the 10th Board of Directors on December 9, 2025, via teleconference to discuss the proposal for the 2025 fourth extraordinary shareholders' meeting [1] - For the first half of 2025, ST Zhongzhu's revenue composition is as follows: hospital income accounts for 56.92%, real estate projects 25.88%, pharmaceutical industry 8.93%, medical devices 4.15%, and center cooperation 3.59% [1] - As of the report date, ST Zhongzhu's market capitalization is 5.3 billion yuan [1] Group 2 - The article also mentions a significant issue in the pharmaceutical industry regarding the abuse of pregabalin, marking the first reported case of addiction in China, highlighting vulnerabilities in online platforms that allow drug purchases without medical records [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 中珠医疗控股股份有限公司（以下简称"中珠医疗"或"公司"）董事会于 2025 年 12 月 1 日收到持股 5%以上股东萧妃英、黄鹏斌各自送达的《提名函》。 鉴于公司第十届董事会非独立董事、独立董事席位出现空缺，为保证公司内控 合法合规，董事会运作正常有序，根据《中华人民共和国公司法》《公司章程》 《董事会议事规则》等规定，股东萧妃英提名房巍屹女士为公司第十届董事会 非独立董事候选人，股东黄鹏斌提名郑颖怡女士为公司第十届董事会独立董事 候选人。具体情况如下： 证券代码：600568 证券简称：ST 中珠 公告编号：2025-068 号 中珠医疗控股股份有限公司 关于股东提名非独立董事候选人、独立董事候选人的公告 特别提示 一、公司董事、独立董事离任情况 2025 年 11 月 27 日，公司董事会收到董事武有先生、独立董事张霞女士送 达的书面辞职报告。 武有先生因个人原因，申请辞去公司董事、董事会审计委员会委员、董事 会薪酬与考核委员会委员职务。辞职后，武有先生不再担任公司任何职 ...

中珠医疗控股股份有限公司 ZhongZhu Healthcare Holding Co.，Ltd 2025 年第四次临时股东会 会议资料 二〇二五年十二月二十五日 中国·珠海 2025 年第四次临时股东会会议资料 目 录 - 2 - 一、2025 年第四次临时股东会会议议程 二、2025 年第四次临时股东会会议须知 三、2025 年第四次临时股东会表决办法 四、会议议案 1、审议《关于补选公司第十届董事会非独立董事候选人的议案》； 2、审议《关于补选公司第十届董事会独立董事候选人的议案》。 2025 年第四次临时股东会会议资料 中珠医疗控股股份有限公司 2025 年第四次临时股东会会议议程 时 间：二〇二五年十二月二十五日 上午 10:00 地 点：珠海市情侣南路 1 号仁恒滨海中心 5 栋 8 层 主持人：董事长陈旭先生 会议议程： 一、主持人宣布现场会议开始。 二、宣读 2025 年第四次临时股东会会议须知。 三、宣读 2025 年第四次临时股东会表决办法。 四、报告出席现场会议的股东人数及其代表的股份总数。 五、推选 2025 年第四次临时股东会现场表决监票人。 六、对下列议案进行审议： 八、现场与会股 ...